Nephrolithiasis and Polycystic Ovary Syndrome: A Case-Control Study Evaluating Testosterone and Urinary Stone Metabolic Panels

Table 1

Bivariate analysis using PCOS status within case-control cohort.

	PCOS (n = 74)		No PCOS (n = 222)		value	N
Mean ± SD age (range)	35.9 ± 11.8	(13–73)	36.0 ± 11.7	(13–73)	0.989	296
Mean ± SD kg/m^2 BMI (range)	31.2 ± 7.4	(17.9–54.5)	31.0 ± 7.3	(18.6–55.0)	0.865	296
Mean ± SD 24 hr urine panel (range):
Calcium (mg/day)	211.2 ± 128.3	(35.5–913.6)	214.7 ± 119.7	(16.7–817.1)	0.848	251
Citrate (mg/day)	624.1 ± 361.9	(82–1903)	527.5 ± 317.8	(4–1546)	0.083	220
Creatinine (g/day)	1.3 ± 0.4	(0.6–3.2)	1.3 ± 0.41	(0.1–2.9)	0.316	230
Oxalate (mg/day)	38.4 ± 15.2	(17–113)	39.1 ± 20.8	(0–180)	0.777	224
Sodium (mmol/day)	135.7 ± 52.0	(49–283)	158.8 ± 76.3	(28–442)	0.015	211
Uric acid (mg/day)	520.2 ± 194.6	(179–1016)	550.1 ± 210.2	(30.3–1361.3)	0.319	231
Volume (ml/day)	1643 ± 793.6	(581–3440)	1690 ± 789.9	(310–4450)	0.712	188
No. abnormality (%):
Hypercalciuria (>200 mg/day)	35	(53.9%)	87	(46.8%)	0.402	251
Hypocitraturia (<550 mg/day)	24	(44.4%)	95	(57.2%)	0.139	220
Hyperoxaluria (>40 mg/day)	20	(34.5%)	58	(34.9%)	1.000	224
Hypernatriuria (>150 mmol/day)	15	(28.9%)	81	(50.9%)	0.009	211
Hyperuricosuria (>750 mg/day)	8	(13.3%)	29	(17.0%)	0.650	231
Low volume (<2000 ml/day)	35	(66.0%)	93	(68.9%)	0.839	188
Mean ± SD stone composition % (range):
CaOMH	45.4 ± 31.2	(0–90)	38.1 ± 31.4	(0–90)	0.286	239
CaODH	16.9 ± 19.0	(0–60)	17.0 ± 20.4	(0–90)	0.985	239
CaPh	25.2 ± 29.0	(0–90)	32.4 ± 34.6	(0–100)	0.270	239
CaHPh	4.6 ± 17.2	(0–80)	2.0 ± 11.7	(0–90)	0.479	239
MAP	2.5 ± 12.3	(0–60)	3.2 ± 12.9	(0–70)	0.791	239
UA	1.7 ± 4.8	(0–20)	3.4 ± 15.9	(0–100)	0.240	239
No. greater than 70% mixed (%)	11	(45.8%)	94	(43.7%)	1.000	239
No. 70% or greater pure (%)					0.261	239
CaOMH	9	(69.2%)	48	(39.7%)
CaODH	0	(0%)	8	(6.6%)
CaPh	3	(23.1%)	54	(44.6%)
CaHPh	1	(7.7%)	3	(2.5%)
MAP	0	(0%)	2	(1.7%)
UA	0	(0%)	6	(5.0%)

Stones qualified as pure if the dominant component made up ≥ 70% of the stone.